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Objectives: To estimate prevalence and risk factors for diagnosis with hyperadrenocorticism in 
dogs attending primary-care veterinary practices in the UK from 2009-2014. 
Methods: Cases were identified by searching de-identified electronic patient records from UK 
primary-care veterinary practices participating in the VetCompass Programme. 
Results: The estimated prevalence for hyperadrenocorticism diagnosis in dogs was 0.28% 
(95% confidence interval 0.25-0.31). Multivariable logistic regression analysis revealed four 
associated risk factors: breed, breed-relative bodyweight, age and insurance status. The Bichon 
Frise had 6.5 times the odds (95% CI 3.5-12.1, P < 0.001) of hyperadrenocorticism compared 
with crossbreds. Dogs weighing more than or equal to their breed mean had 1.7 times odds 
(95% CI 1.3-2.3, P < 0.001) of hyperadrenocorticism compared with dogs weighing less than 
the breed mean. Dogs aged 12.0 years and above showed 5.7 times the odds (95% CI 3.7-8.7, 
P < 0.001) of hyperadrenocorticism compared with dogs aged 6.0-8.9 years. Insured dogs had 
4.0 times the odds (95% CI 2.8-5.6, P < 0.001) of hyperadrenocorticism compared with non-
insured dogs.  
Clinical significance: This is the first epidemiological report of a non-referral hospital 
population of dogs diagnosed with hyperadrenocorticism in the UK and describes important 
breed, age and bodyweight associations with this disorder which may improve diagnosis and 
enhance understanding of the underlying pathophysiology.  
 






Hyperadrenocorticism results from chronic overproduction of cortisol (Behrend et al., 2015, 
Melian et al., 2010) and generally results from either a functional pituitary tumour (PTHAC) 
or adrenal tumour (ATHAC), although other causes are also recognised (Galac et al., 2005, 
Galac et al., 2008). Traditionally most dogs affected by hyperadrenocorticism show polyuria, 
polydipsia, polyphagia, muscle atrophy and dermatological changes such as alopecia and 
cutaneous hyperpigmentation (Ling et al., 1979, Lorenz, 1982, Reusch and Feldman, 1992, 
White et al., 1989). Studies from the USA estimate the prevalence of PTHAC to be around 
0.2% and the incidence of new hyperadrenocorticism cases as 1 to 2 cases/1000 dogs/year 
(Bruyette et al., 2010, Lourenc et al., 2015, Willeberg and Priester, 1982). To date there have 
been no studies reporting the prevalence of hyperadrenocorticism for dogs in the UK.  
 Several risk factors for the development of canine hyperadrenocorticism have been described, 
including older age and breeds such as the Miniature Poodle, Boxer and Dachshund (Behrend 
et al., 2015, Burkhardt et al., 2013, Ling et al., 1979, Lourenc et al., 2015, Reusch and Feldman, 
1992, Fracassi et al., 2014). Female dogs have been over-represented in some studies 
describing hyperadrenocorticism but this finding has not been universally identified (Gallelli 
et al., 2010, Reusch and Feldman, 1992). Due to potential environmental and genetic 
differences between dog populations across geography and time, the results from non-UK or 
older studies may be poorly translatable to the current general UK dog population (Wilson and 
Wade, 2012). 
 
Several studies have described the clinical features of canine hyperadrenocorticism in the UK 
(Augusto et al., 2012, Helm et al., 2011, Neiger et al., 2002, Kenefick and Neiger, 2008, Barker 
et al., 2005). These describe a mean age at diagnosis between 8 to 11 years, with toy and terrier 
breeds overrepresented and suggest female dogs may have an increased risk for ATHAC, but 
not PTHAC (Helm et al., 2011, Kenefick and Neiger, 2008, Neiger et al., 2002). PTHAC 
accounts for around 77% of cases of UK canine hyperadrenocorticism, similar to findings in 
non-UK studies (Augusto et al., 2012, Reusch and Feldman, 1992). However, the majority of 
these studies describe dogs from referral populations and therefore the results may be poorly 
generalizable to the wider dog population (Bartlett et al., 2010).  
 
This study aimed to describe the signalment, prevalence and risk factors in dogs diagnosed 
with hyperadrenocorticism in primary-care practice in the UK that were participating in the 
VetCompass Programme from 2009-2014 and to describe diagnostic testing protocols and 
outcomes for these cases. A main focus of the study was to identify UK breeds at higher risk 
of diagnosis with hyperadrenocorticism. The study hypothesised that sex was not associated 
with risk of diagnosis with hyperadrenocorticism. 
 
Materials and methods 
 
The VetCompass companion animal surveillance programme (VetCompass, 2015) collates de-
identified electronic patient record (EPR) data from primary-care veterinary practices in the 
UK for epidemiological research (O'Neill et al., 2014b). Collaborating practices were selected 
by their willingness to participate and their recording of clinical data within an appropriately 
configured practice management system (PMS). Practitioners could record summary diagnosis 
terms from an embedded VeNom Code list (The VeNom Coding Group, 2015) during episodes 
of care. Information collected related mainly to the owned dog population and included patient 
demographic (species, breed, date of birth, sex, neuter status, insurance status and bodyweight) 
and clinical information (free-form text clinical notes, summary diagnosis terms, treatment and 
deceased status with relevant dates) data fields. EPR data were extracted from PMSs using 
integrated clinical queries (O'Neill et al., 2014b) and uploaded to a secure VetCompass 
structured query language (SQL) database.   
 
A cross-sectional study design was used to estimate the prevalence and risk factors for 
hyperadrenocorticism. The sampling frame for the current study included all dogs with at least 
one EPR (clinical note, VeNom summary term, bodyweight or treatment) uploaded to the 
VetCompass database from September 1st, 2009 to August 31st, 2014. Sample size calculations 
estimated a cross-sectional study with 41,339 male and 41,339 female animals would have 80% 
power to detect sex as a risk factor with an odds ratio of 1.2 or greater (two-sided =0.05) 
having a 0.2% prevalence in the less-predisposed sex (Epi  Info 7 CDC, 2015). Ethics approval 
was granted by the RVC Ethics and Welfare Committee (reference number 2014/S45).  
 
The hyperadrenocorticism case definition required the dog had a final diagnosis of 
hyperadrenocorticism (or synonym) recorded in the EPR. The case inclusion criteria relied on 
the clinical acumen of UK veterinary practitioners to make primary-care diagnoses and did not 
demand any specific diagnostic protocols for hyperadrenocorticism. This approach also 
enabled the study to report on the diagnostic protocols that were used across all     diagnosed 
hyperadrenocorticism cases. A two-stage case-finding process was used. In stage one, all study 
dogs were screened to identify candidate hyperadrenocorticism cases by searching the clinical 
free-text field (search terms: PDH, ADH, hyperadren, cushing, adrenalec, adrenomeg), the 
VeNom term field (search term: hyperadrenocorticism) and the treatment field (drug searches: 
vetoryl, Lysodren, DDD, Mitotane, Trilostane and deprenyl). In stage two, the full EPRs of a 
random subset of candidate hyperadrenocorticism cases were manually reviewed to decide on 
case inclusion. Randomisation used the RAND function in Microsoft Excel (Microsoft Office 
Excel 2007, Microsoft Corp.). Additional data were extracted on confirmed 
hyperadrenocorticism cases that described whether the case was pre-existing (first recorded 
prior to the study period) or incident (first recorded during the study period), the date of first 
diagnosis and the laboratory tests used during diagnosis (for incident cases only) and the date 
and mechanism of any deaths. All dogs that were not identified as candidate 
hyperadrenocorticism cases during the initial screening were included as non-cases for 
hyperadrenocorticism in the risk factor analysis.  
 A purebred variable grouped all dogs recorded as a recognisable breed (Irion et al., 2003) as 
‘purebred’ and all other dogs as ‘crossbred’. A breed variable included 16 categories: the 12 
most common breeds overall in the study, two other breeds with ≥ 10 incident 
hyperadrenocorticism cases, a grouping of all remaining breeds and a grouping of all crossbred 
dogs. A KC breed group variable classified breeds recognised by the Kennel Club (KC) into 
their relevant KC breed groups (Gundog, Hound, Pastoral, Terrier, Toy, Utility, Working) and 
all remaining dogs were classified as non-KC recognised. Neuter described the status of the 
dog (entire or neutered) as recorded at the final EPR. Insurance described whether a dog was 
insured at any point during the study period. The age value described the age at the date of first 
diagnosis for incident hyperadrenocorticism cases and was entered as unknown for pre-existing 
hyperadrenocorticism cases. For non-case dogs, the age described the age at the mid-point 
between the dates of the first and final EPRs recorded during the study period. All risk factors 
except age were included as ‘fixed’ for both the pre-existing and incident cases i.e. their 
exposure status was not affected by the date of first diagnosis of hyperadrenocorticism and 
therefore the risk factor analysis could be interpreted as comparing the odds of ‘being a case’.  
On the other hand, by using the specific age value at the point that the incident cases became 
first diagnosed with hyperadrenocorticism,  the risk factor results for the effect of age could be 
interpreted comparing the odds at each age group for ‘becoming a case’ (Robins and Hernán, 
2009).  
 
Age (years) was categorised into six groups (< 3.0, 3.0-5.9, 6.0-8.9, 9.0-11.9, ≥ 12.0, not 
recorded). Actual bodyweight described the maximum bodyweight recorded during the study 
period for dogs older than nine months and was categorised into six groups (0.0-9.9 kg, 10.0-
19.9 kg, 20.0-29.9 kg, 30.0-39.9 kg, ≥ 40.0 kg, not recorded). Breed-relative bodyweight 
characterised dogs with a recorded bodyweight when aged older than nine months as being 
either below or equal/above the mean adult bodyweight of its breed from the overall dataset. 
Dogs without a bodyweight value recorded when they were aged older than nine months were 
included as ‘not recorded’.  This variable allowed the effect of bodyweight variation within 
breeds to be assessed. The time contributed to the study for each dog described the period from 
the dates of the earliest to the latest EPR.  
 
Data checking and cleaning was performed in Excel (Microsoft Office Excel 2007, Microsoft 
Corp.) and evaluated internal data consistency, missing values and outlier data. All analyses 
were conducted using Stata Version 13 (Stata Corporation). The period prevalence with 95% 
confidence intervals (CI) described the probability of dogs having hyperadrenocorticism at any 
time during the study period and included dogs that were first diagnosed with 
hyperadrenocorticism prior to the study period (pre-existing cases) as well as those diagnosed 
for the first time during the study period (incident cases). The CI estimates were derived from 
standard errors based on approximation to the normal distribution (Kirkwood and Sterne, 
2003).  
 
Because the sampling design involved manual verification of a subset of the candidate cases, 
the count of cases that would have been identified if the entire set of candidate cases had been 
manually verified was calculated by weighting the verified case numbers by the inverse of the 
proportion of candidate cases that was manually verified. The estimated total 
hyperadrenocorticism case count was used to estimate overall and breed prevalence values 
based on a denominator of all study dogs either overall or by breed respectively. The prevalence 
CI estimates were derived from standard errors, based on approximation to the normal 
distribution (Kirkwood and Sterne, 2003). Descriptive statistics characterised the breed, sex, 
neuter status, insurance status, age and bodyweight separately for the case and non-case dogs. 
Diagnostic tests used to support the hyperadrenocorticism diagnosis were reported for incident 
cases only. The chi-square test was used to compare categorical variables (Kirkwood and 
Sterne, 2003). 
 
Binary logistic regression modelling was used to evaluate univariable associations between 
risk factors (purebred, breed, KC breed group, actual bodyweight, breed-relative bodyweight, 
age, sex, neuter and insurance) and hyperadrenocorticism.  Both pre-existing and incident 
hyperadrenocorticism cases were included in risk factor analysis. Because breed was a factor 
of primary interest for the study, purebred and KC breed group (collinear with breed) and 
actual bodyweight (a defining characteristic of individual breeds) were excluded from 
multivariable modelling but univariable analysis results were reported. Remaining risk factors 
with liberal associations in univariable modelling (P < 0.2) were taken forward for 
multivariable evaluation. Model development used manual backwards stepwise elimination. 
Clinic attended was evaluated as a random effect and pair-wise interaction effects were 
evaluated in the final model (Dohoo et al., 2009). The area under the ROC curve was used to 
evaluate the quality of the model fit (non-random effect model) (Dohoo et al., 2009). Statistical 




The overall dataset comprised 210,824 dogs attending 119 clinics in England. There were 4,846 
candidate hyperadrenocorticism cases identified. Manual checking of a random sample of 
2,535 (52.3%) candidate cases identified 304 dogs that met the hyperadrenocorticism case 
definition. Many of the excluded animals included hyperadrenocorticism within differential 
diagnosis lists but the disorder was not later confirmed. Of the confirmed hyperadrenocorticism 
cases, 113 (37.2%) were pre-existing and 191 (62.8%) were incident cases. Following removal 
of the residual 4,542 candidate cases, there were 304 cases and 205,978 non-cases included in 
the descriptive and inferential statistics. The median time contributed to the study across all 
dogs in the study was 0.6 years (interquartile range [IQR]: 0.0-2.1 years, range 0.0-5.0 years).  
After accounting for the effects of the subsampling protocol by weighting the verified case 
numbers by the inverse of the proportion of candidate cases that was manually verified as 
described in the methods section, the estimated prevalence for hyperadrenocorticism diagnosis 
in dogs was 0.28% (95% CI 0.25-0.30). The breed prevalence results indicated that the breeds 
with the highest hyperadrenocorticism prevalence were the Standard Dachshund (2.6%, 95% 
CI 1.6-4.0) and Bichon Frise (1.6%, 95% CI 1.2-2.2) (Table 2).   
Data completion varied between the variables assessed: breed 99.9%, sex 99.5%, neuter status 
46.4%, insurance 65.7%, age 99.7% and bodyweight 65.4%. Of the hyperadrenocorticism dogs 
with complete information available (not including those animals with missing data), 241 (79.3 
%) were purebred, 152 (50.0%) were female, 205 (86.1%) were neutered and 161 (53.0%) were 
insured. The median bodyweight was 12.5 (IQR: 9.1-22.0, range: 2.5-58.7) kg and the median 
age at diagnosis was 10.9 (IQR: 9.5-12.8, range: 2.4-18.0) years (Figure 1). The most common 
breeds diagnosed with hyperadrenocorticism were the Jack Russell Terrier (n = 29, 9.5%), 
Bichon Frise (n = 24, 7.9%), Yorkshire Terrier (n = 22, 7.2%), Staffordshire Bull Terrier (n = 
17, 5.6%) and West Highland White Terrier (n = 13, 4.3%) (Table 1).  
 
Of the non-case dogs with information available, 159,422 (77.4%) were purebred, 97,985 
(47.8%) were female, 73,497 (78.0%) were neutered and 47,696 (40.3%) were insured. The 
median bodyweight was 17.8 (IQR: 9.2-28.7, range: 0.7-112.0) kg and the median age was 3.9 
(IQR: 1.3-8.0, range: 0.0-30.8) years (Figure 1). The most common breeds among non-
hyperadrenocorticism dogs were the Labrador Retriever (n= 17,406, 8.5%), Staffordshire Bull 
Terrier (n = 16,473, 8.0%), Jack Russell Terrier (n = 13,198, 6.4%) and Cocker Spaniel (n = 
7,507, 3.6%) (Table 1). Among the overall study dogs, purebred dogs had a higher probability 
of being insured than crossbred dogs (41.9% versus 37.4% respectively, P < 0.001). 
 
Figure 1. Ages at the mid-point between the dates of the first and final clinical records 
during the study period for dogs without a diagnosis of hyperadrenocorticism (n = 
209,991) and at the date of first diagnosis for dogs with a diagnosis of 





Table 1: Descriptive and univariable logistic regression results for risk factors associated 
with hyperadrenocorticism in dogs attending primary-care veterinary practices in 













Crossbred 63 (20.7) 46,425 (22.6) Base   
 Purebred 241 (79.3) 
159,422 
(77.4) 
1.1 0.8-1.5 0.446 
Breed Crossbred 63 (20.7) 46,425 (22.5) Base   











 Shih-tzu 8 (2.6) 4,051 (2.0) 1.5 0.7-3.0 0.318 




29 (9.5) 13,198 (6.4) 1.6 1.0-2.5 0.032 




13 (4.3) 5,019 (2.4) 1.9 1.0-3.5 0.034 




17 (5.6) 16,473 (8.0) 0.8 0.4-1.3 0.317 








3 (1.0) 7,025 (3.4) 0.3 0.1-1.0 0.050 




3 (1.0) 4,035 (2.0) 0.5 0.2-1.7 0.309 





Working 8 (2.6) 11,278 (5.5) 0.5 0.2-1.0 0.047 
 Hound 25 (8.2) 9,083 (4.4) 1.9 1.2-2.9 0.006 
 Toy 56 (18.4) 24,839 (12.1) 1.5 1.1-2.1 0.013 
 Terrier 55 (18.1) 28,621 (13.9) 1.3 0.9-1.8 0.124 
 Utility 30 (9.9) 16,894 (8.2) 1.2 0.8-1.8 0.383 
 Pastoral 12 (4.0) 15,291 (7.4) 0.5 0.3-1.0 0.039 
 Gundog 26 (8.6) 37,590 (18.3) 0.5 0.3-0.7 0.001 




< 10.0 105 (34.5) 38,139 (18.5) 3.0 1.5-5.9 0.002 
 10.0-19.9 101 (33.2) 35,270 (17.1) 3.1 1.6-6.2 0.001 
 20.0-20.9 53 (17.4) 29,711 (14.4) 1.9 1.0-3.9 0.067 
 30.0-30.9 27 (8.9) 20,485 (10.0) 1.4 0.7-3.0 0.351 
 ≥ 40.0 9 (3.0) 9,779 (4.8) Base   





< Breed Average 116 (38.2) 73,888 (35.9) Base   
 ≥ Breed Average 179 (58.9) 59,496 (28.9) 1.9 1.5-2.4 < 0.001 
 Not recorded 9 (3.0) 72,594 (35.2) 0.1 0.0-0.2 < 0.001 
Age* 
(years)  
< 3.0 1 (0.3) 86,930 (42.2) 0.0 0.0-0.1 < 0.001 
 3.0 - 5.9 4 (1.3) 43,278 (21.0) 0.1 0.0-0.3 < 0.001 
 6.0 - 8.9 32 (10.5) 32,152 (15.6) Base   
 9.0 - 11.9 81 (26.6) 23,169 (11.2) 3.5 2.3-5.3 < 0.001 
 ≥ 12.0 73 (24.0) 19,922 (9.7) 3.7 2.4-5.6 < 0.001 




Sex Female 152 (50.0) 97,985 (47.8) Base   
 Male 152 (50.0) 
106,999 
(52.2) 
0.9 0.7-1.1 0.443 
Neuter Entire 33 (10.9) 20,736 (10.1) Base   
 Neutered 205 (67.4) 73,497 (35.7) 1.8 1.2-2.5 0.003 
 Not recorded 66 (21.7) 
111,745 
(54.32 
0.4 0.2-0.6 < 0.001 
Insurance Non-insured 87 (28.6) 70,696 (34.3) Base   
 Insured 161 (53.0) 47,696 (23.2) 2.7 2.1-3.6 < 0.001 
 Not recorded 56 (18.4) 87,586 (42.5) 0.5 0.4-0.7 < 0.001 




Table 2: Estimated prevalence of hyperadrenocorticism in common dog breeds attending 
primary-care veterinary practices in England. The case counts from a 37.2% sample of 





Total no. cases 
(estimated) 





Crossbred 63 120 47300 0.25 0.2-0.3 
Bichon Frise 24 46 2839 1.62 1.2-2.2 
Standard Dachshund 10 19 737 2.58 1.6-4.0 
Shih-tzu 8 15 4151 0.36 0.2-0.6 
Yorkshire Terrier 22 42 6980 0.6 0.4-0.8 
Jack Russell Terrier 29 55 13520 0.41 0.3-0.5 
Chihuahua 2 4 4619 0.09 0.0-0.2 
West Highland White 
Terrier 
13 25 5275 0.47 0.3-0.7 
Staffordshire Bull 
Terrier 
17 32 16746 0.19 0.1-0.3 
Cocker Spaniel 7 13 7699 0.17 0.1-0.3 
Cavalier King Charles 
Spaniel 
5 10 4461 0.22 0.1-0.4 
German Shepherd Dog 3 6 7112 0.08 0.0-0.2 
Labrador Retriever 11 21 17770 0.12 0.1-0.2 
English Springer 
Spaniel 
3 6 4131 0.15 0.1-0.3 
Border Collie 1 2 5453 0.04 0.0-0.1 
 
 
During the protocols used to diagnose the 191 incident hyperadrenocorticism cases, the 
following diagnostic tests were utilised: ACTH (adrenocorticotrophic hormone) stimulation 
test 182 (95.3%), urine cortisol-creatinine ratio 53 (27.8%), low dose dexamethasone 
suppression test (LDDST) 63 (33.0%), high dose dexamethasone suppression test (HDDST) 4 
(2.1%), endogenous ACTH assay 8 (4.2%), adrenal ultrasonography 50 (26.2%) and magnetic 
resonance imaging 2 (1.1%). While differentiation between PTHAC and ATHAC is an 
important aspect of hyperadrenocorticism diagnosis, this distinction was infrequently recorded 
in the EPRs of the current study (Behrend et al., 2013). 
 During the study period, 127 (41.8%) of the 304 dogs with hyperadrenocorticism died from 
any cause. These deaths were at a median age of 12.7 years (interquartile range 10.9-14.2, 
range 5.8-17.6). From 119 deceased dogs with information available, 105 (88.2%) of the deaths 
involved euthanasia. Of the incident cases, 77/191 (40.3%) died during the study period. No 
significant differences were identified between purebred and crossbred dogs (P = 0.637) or 
between the individual breed assessed (P = 0.293) for the probability of incident cases dying 
during the study. However, male incident cases (48/100, 48.0% died) were more likely to die 
during the study period (P = 0.023) than females (29/91, 31.9%). 
 
Univariable logistic regression modelling identified seven variables with liberally significant 
(P < 0.20) association with hyperadrenocorticism diagnosis: breed, KC breed group, actual 
bodyweight, breed-relative bodyweight, age, neuter and insurance (Table 1). As explained 
above, purebred, KC breed group and actual bodyweight were not considered for multivariable 
modelling. Based on the results of univariable analysis, no significant difference was detected 
between purebred compared with crossbred dogs in their odds of hyperadrenocorticism (odds 
ratio [OR] 1.1, 95% CI 0.8-1.5, P = 0.446). Among the KC breed groups, Hounds (OR 1.9, 
95% CI 1.2-2.9, P = 0.006) and Toys (OR 1.5, 95% CI 1.1-2.1, P = 0.013) showed higher odds 
of hyperadrenocorticism than KC non-recognised dogs, while Gundogs (OR 0.5, 95% CI 0.3-
0.7, P = 0.001), Pastorals (OR 0.5, 95% CI 0.3-1.0, P = 0.039) and Working dogs (OR 0.5, 
95% CI 0.2-1.0, P = 0.047) had reduced odds of hyperadrenocorticism. Dogs of actual 
bodyweight < 10.0 kg had 3.0 times the odds (95% CI 1.5-5.9, P = 0.002) and those of 
bodyweight from 10.0-19.9 kg had 3.1 times the odds of hyperadrenocorticism (95% CI 1.6-
6.2, P = 0.001) compared with dogs weighing ≥ 40.0 kg. 
  Following evaluation using multivariable logistic regression, the final model comprised four 
risk factors: breed, breed-relative bodyweight, age and insurance. No biologically significant 
interactions were identified. The final model was improved by inclusion of the clinic attended 
as a random effect and these results are reported (P < 0.001, rho = 0.094 indicating that the 
clinic attended accounted for 9.4% of variation). The final non-clustered model showed good 
discrimination (area under the ROC curve: 0.949). After accounting for the effects of the other 
variables evaluated, the Bichon Frise showed strong evidence of higher odds of 
hyperadrenocorticism compared with crossbred dogs (OR: 6.5, 95% CI 3.5-12.1, P < 0.001) 
while the Standard Dachshund (OR: 3.4, 95% CI 0.9-13.3, P = 0.083) and Yorkshire Terrier 
(OR: 1.8, 95% CI 1.0-3.4, P = 0.055) showed some evidence of increased odds. The Border 
Collie (OR: 0.1, 95% CI 0.0-0.9, P = 0.038) and Labrador Retriever (OR: 0.3, 95% CI 0.1-0.7, 
P = 0.003)) showed decreased odds of hyperadrenocorticism compared with crossbred dogs. 
Dogs with bodyweight equal to or higher than their breed mean had a 1.7 times odds of 
diagnosis compared with dogs weighing below their breed mean (95% CI 1.3-2.3, P < 0.001). 
Increasing age was associated with increasing odds of hyperadrenocorticism; dogs aged 9.0-
11.9 years showed 3.9 (95% CI 2.6-6.0, P < 0.001) times the odds and dogs aged ≥ 12.0 years 
showed 5.7 (95% CI 3.7-8.7, P < 0.001) times the odds of diagnosis with hyperadrenocorticism 
compared with dogs aged 6.0-8.9 years. Insured dogs had 4.0 times the odds of diagnosis with 
hyperadrenocorticism compared with non-insured dogs (95% CI 2.8-5.6, P < 0.001) (Table 3).  
 
Table 3: Final mixed-effects multivariable logistic regression model for risk factors 
associated with diagnosis of hyperadrenocorticism in dogs attending primary-care 







Breed Crossbred Base   
 Bichon Frise 6.5 3.5-12.1 < 0.001 
 Standard Dachshund 3.4 0.9-13.3 0.083 
 Shih-tzu 1.8 0.7-4.6 0.197 
 Yorkshire Terrier 1.8 1.0-3.4 0.055 
 Jack Russell Terrier 1.5 0.9-2.6 0.128 
 Chihuahua 1.4 0.3-5.8 0.649 
 
West Highland White 
Terrier 
1.1 0.5-2.3 0.789 
 Other breeds 1.0 0.7-1.5 0.900 
 Staffordshire Bull Terrier 0.9 0.5-1.8 0.790 
 Cocker Spaniel 0.7 0.3-1.7 0.465 
 
Cavalier King Charles 
Spaniel 
0.6 0.2-2.0 0.445 
 German Shepherd Dog 0.4 0.1-1.4 0.172 
 Labrador Retriever 0.3 0.1-0.7 0.003 
 English Springer Spaniel 0.2 0.0-1.2 0.088 
 Border Collie 0.1 0.0-0.9 0.038 
     
Breed- relative 
bodyweight 
< Breed Average Base   
 ≥ Breed Average 1.7 1.3-2.3 < 0.001 
 Not recorded 0.0 0.0-0.0 < 0.001 
     
Age* (years) < 3.0 0.0 0.0-0.2 < 0.001 
 3.0 - 5.9 0.1 0.0-0.3 < 0.001 
 6.0 - 8.9 Base   
 9.0 - 11.9 3.9 2.6-6.0 < 0.001 
 ≥ 12.0 5.7 3.7-8.7 < 0.001 




     
Insurance Non-insured Base   
 Insured 4.0 2.8-5.6 < 0.001 
 Not recorded 1.1 0.7-1.7 0.754 






This study reports the estimated prevalence of diagnosis with canine hyperadrenocorticism in 
the UK as 0.28%, suggesting hyperadrenocorticism is the third most prevalent endocrinopathy 
of dogs behind hypothyroidism (0.87%) (Dixon et al., 1999) and diabetes mellitus (0.34%) 
(Mattin et al., 2014), although methodological differences between the various studies 
complicate direct prevalence comparisons. Despite several molecular studies that investigated 
its aetiopathogenesis, the exact cause of hyperadrenocorticism in most dogs remains unknown 
(Hanson et al., 2010, Kool et al., 2013, Teshima et al., 2009, van Rijn et al., 2010, van Wijk et 
al., 2014). Access to clinical health data on the large population of dogs in VetCompass offers 
the intriguing prospect of aetiological and epidemiological research across a range of disorders 
such as hyperadrenocorticism and of linking these with primary-care diagnosis and health 
management (Mattin et al., 2014, Kearsley-Fleet et al., 2012, Taylor-Brown et al., 2015, Mattin 
et al., 2015, O'Neill et al., 2013).   
 
The ACTH stimulation test was by far the most commonly test used during 
hyperadrenocorticism diagnosis in the current study, with over 95% of diagnoses including this 
test. The ACTH stimulation test has previously been reported as a commonly-used test for 
hyperadrenocorticism diagnosis in the UK (Barker et al., 2005, Kenefick and Neiger, 2008, 
Neiger et al., 2002). The ACTH stimulation test is diagnostically more specific, with reported 
test specificities ranging from 59% to 93%, but less sensitive than the LDDST (Behrend et al., 
2013). The predominance of the ACTH stimulation test in the current study should have 
resulted in fewer false positive diagnoses of hyperadrenocorticism than if the LDDST was the 
predominant test. The LDDST is currently considered the screening test of choice for the 
diagnosis of hyperadrenocorticism and can assist with differentiating between PTHAC and 
ATHAC (Behrend et al., 2013, Feldman et al., 1996) but was performed in only one third of 
cases in the current study. Although diagnostic specificity is lower for LDDST than the ACTH 
stimulation test, appropriate case selection on those patients presenting with highly suggestive 
history, clinical signs, and routine haematology and biochemistry should reduce false positives. 
The ACTH stimulation test may be preferred in primary-care practice to the LDDST because 
it is faster to perform and more convenient for owners.  
The guidelines published in the Diagnosis of Canine Spontaneous Hyperadrenocorticism 
ACVIM Consensus Statement strongly recommend differentiation between the ATHAC and 
PTHAC variants of hyperadrenocorticism (Behrend et al., 2013). However, this distinction 
between PTHAC and ATHAC was infrequently recorded in the EPRs of the current study. The 
LDDST can differentiate PTHAC from ATHAC in approximately two-thirds of cases and, with 
specialist equipment and operator skills, adrenal ultrasonography has a high diagnostic 
sensitivity and specificity (82–100% and 82–99%, respectively) for the diagnosis of ATHAC 
(Behrend et al., 2015, Benchekroun et al., 2010). Increased awareness of the importance of this 
differentiation step should improve the management of hyperadrenocorticism-affected dogs.  
 
This study identified evidence that the Bichon Frise (OR 6.5), Standard Dachshund (OR 3.4) 
and Yorkshire Terrier (OR 1.8) are predisposed to hyperadrenocorticism. Indeed, one in forty 
Standard Dachshunds and one in sixty Bichon Frise dogs were affected by 
hyperadrenocorticism in the current study (Table 2). Although familial hyperadrenocorticism 
has been described in Wire-Haired Dachshunds, spontaneous hyperadrenocorticism still 
accounts for the vast majority of cases in this breed (Stritzel et al., 2008). Dachshunds have 
been identified as predisposed in several hyperadrenocorticism studies but the predisposition 
identified for the Bichon Frise in the current study is novel (Hanson et al., 2007, Helm et al., 
2011, Jensen et al., 1997, Ling et al., 1979, Peterson, 1984). The Border Collie and Labrador 
Retriever were identified as protected breeds in the current study, with 0.1 and 0.3 times the 
odds for hyperadrenocorticism respectively compared with crossbreds. The reduced odds of 
hyperadrenocorticism in the Labrador Retriever shown in the current study is of interest 
because gundogs in general have previously been reported to have a reduced risk of 
hyperadrenocorticism in the UK (Barker et al., 2005). However, it is important that 
practitioners still remain alert for hyperadrenocorticism in non-predisposed breeds that are 
populous in the general population (e.g. Jack Russell Terrier and Staffordshire Bull Terriers) 
because these breeds can still contribute substantially to overall hyperadrenocorticism 
caseloads because of their popularity in the wider dog population (Table 1).  
 
Of the KC breed groups, the Toy group had 1.5 times the odds of hyperadrenocorticism 
compared with breeds unrecognised by the KC, in line with previous reports (Barker et al., 
2005). Two of the three individual breeds (Bichon Frise and Yorkshire Terrier) with evidence 
of over-representation for hyperadrenocorticism are among the Toy group and, together, these 
two breeds accounted for 15% of all hyperadrenocorticism diagnoses in this study population. 
The Hound group also had an increased risk of hyperadrenocorticism, with almost twice the 
odds of hyperadrenocorticism compared with breeds unrecognised by the KC. This can be 
explained by the presence of the Standard Dachshund in this group, which accounted for 40% 
of all Hounds diagnosed with hyperadrenocorticism. The Gundog, Working and Pastoral each 
had half the odds of hyperadrenocorticism compared with non-KC breed dogs. Members of 
these groups are generally medium to large bodysize breeds, and the univariable results 
suggested dogs of larger bodyweight had lower hyperadrenocorticism risk compared with 
smaller bodysize and toy breed dogs.  
 Individuals with a bodyweight equal to or higher than their breed mean had almost twice the 
odds of hyperadrenocorticism compared with dogs weighing below their breed mean. It is 
possible that dogs with higher average bodyweight are more likely to be overweight and 
therefore these results may suggest that overweight/obesity may be associated with 
hyperadrenocorticism in dogs.  Previous reports have also suggested that dogs with a higher 
body condition score were at higher risk of hyperadrenocorticism than dogs with normal or low 
body condition scores, and an association between obesity and increased hyperadrenocorticism 
risk is recognised in human medicine (Lund et al., 2006, Tiryakioglu et al., 2010). However, 
these earlier studies reported associations rather than causal relationships and there are clearly 
other possible non-causal explanations for this association. For example, increased bodyweight 
in hyperadrenocorticism cases may be a consequence rather than a contributor to 
hyperadrenocorticism risk since dogs with hyperadrenocorticism are likely to demonstrate 
varying degrees of polyphagia and hence have increased risk of weight gain (Ramsey and 
Ristic, 2007). Future work to collect data on body condition score from dogs within the 
VetCompass database could help to clarify these associations.  
 
The current study identified increasing risk of hyperadrenocorticism as animals age that has 
also been reported in other studies (Gallelli et al., 2010, Willeberg and Priester, 1982). The 
median age at diagnosis of hyperadrenocorticism in the current study was 10.9 years. Multi-
centre studies performed in the UK described 37 dogs with a diagnosis of ATHAC having a 
mean age of 11.5 years (S.D. 1.87 years) and 148 dogs with a diagnosis of PTHAC having a 
mean age of 9.6 years (S.D. 2.3 years) (Barker et al., 2005, Helm et al., 2011). These ages are 
similar to the peak cancer incidence in a population of insured UK dogs (Dobson et al., 2002). 
Many tumours are caused by spontaneous somatic mutations and are more likely to become 
clinically significant as individuals age, possibly explaining why the risk of 
hyperadrenocorticism diagnosis increases with age (Kennedy et al., 2012). It should be noted 
that the large number of cases without an apparent age shown in Tables 1 & 2 was because pre-
existing cases were included in the study as having no recorded ‘age-at-diagnosis’.  
Although some previous studies reported a female predisposition for hyperadrenocorticism, 
this finding has often not been confirmed in other studies (Gallelli et al., 2010, Reusch and 
Feldman, 1992, Kenefick and Neiger, 2008, Neiger et al., 2002). The results of the current 
study supported the study hypothesis that sex is not a risk factor for a diagnosis of 
hyperadrenocorticism in dogs. In human medicine, hyperadrenocorticism has a substantial 
female over-representation, with female-to-male ratios commonly reported as 3:1 but the cause 
for this female predisposition in humans remains unclear (Boscaro et al., 2001, Huan et al., 
2014, Newell-Price et al., 2014). In contrast to male humans who have an increased risk of 
large corticotroph tumours, large pituitary tumours have been reported as more common in 
female dogs (Gallelli et al., 2010, Huan et al., 2014, Zilio et al., 2014). This suggests differing 
aetiopathogenesis of PTHAC between humans and dogs. Larger pituitary tumours are 
associated with poorer prognosis, so it is possible that sex could affect outcome (Gallelli et al., 
2010, Hanson et al., 2007, Kent et al., 2007). Female dogs did not have an increased odds of 
death compared with males in a recent European study (Fracassi et al., 2014). However, among 
hyperadrenocorticism cases, the current study identified a higher risk for males than females 
to die during the study period. Further work is needed to examine associations between sex, 
aetiopathogenesis and survival in more detail.  
 
Testosterone has been shown to inhibit ACTH and cortisol secretion in rat models (Ajdžanović 
et al., 2015, Handa et al., 1994) and, if similar physiological pathways exist in dogs, a release 
of suppression might contribute to hyperadrenocorticism in neutered dogs. However, the 
current study did not detect an increased odds of a diagnosis of hyperadrenocorticism in 
neutered dogs after accounting for age and other risk factors.  Similarly, a recent abstract 
describing an American population of dogs diagnosed with hyperadrenocorticism also failed 
to identify a differing risk of hyperadrenocorticism between neutered and intact dogs (Lourenc 
et al., 2015). In relation to the use of a standardised ACTH stimulation test using a ‘genderless’ 
reference range for the diagnosis of hyperadrenocorticism, it is interesting to note healthy 
neutered male dogs had higher serum post-ACTH cortisol concentrations than entire males 
(Frank et al., 2003). It has been suggested entire dogs may require a different reference interval 
for ACTH stimulation tests and that this group may be currently under-diagnosed if the same 
reference interval as neutered males is used (Frank et al., 2003).  
 
The finding that insured dogs had increased odds of a diagnosis of hyperadrenocorticism 
mirrors other studies that show higher diagnostic proportions in insured compared with non-
insured dogs, especially in disorders where diagnostic protocols are expensive or complicated 
(Taylor-Brown et al., 2015, Shoop et al., 2015, O'Neill et al., 2013). Increased disorder 
diagnosis may result from insured dogs being more likely to undergo diagnostic investigations 
than non-insured dogs (Egenvall et al., 2009). Hyperadrenocorticism is a chronic disease and 
treated patients generally require protracted therapeutic monitoring with consequent significant 
expense. It is estimated the actual lifetime cost of owning a dog in the UK is £16,000-31,000 
and it is likely that diagnostic and treatment costs that can be triggered by unexpected illness 
may be poorly affordable for some owners of uninsured dogs (PDSA, 2015).  
 The study had some limitations. Due to time constraints, just over half of the possible cases 
identified in the original search strategy underwent manual verification. This complicated the 
calculation of prevalence estimates but should not have affected the overall findings of the 
study because of the sizeable number of cases that were still verified and because a randomised 
process was used to select the subset of candidate animals that were manually verified. As 
previously described for other published VetCompass studies, these data were not recorded 
primarily for research purposes and thus were limited by both missing or incomplete data and 
potential misdiagnoses (O'Neill et al., 2014a, O'Neill et al., 2014b)(O’Neill et al., 2015, 2013; 
O′Neill et al., 2014). Many cases did not undergo testing to differentiate between PTHAC and 
ATHAC, and consequently we have analysed the data by combining PTHAC and ATHAC 
cases as a general hyperadrenocorticism diagnosis. Although this paper accurately describes 
the prevalence of diagnosed hyperadrenocorticism recorded in the current study, this value may 
be an underestimate of the true prevalence of hyperadrenocorticism in this population because 
some positive cases may not have been diagnosed because of clinical or financial constraints.      
In conclusion, this study estimated that hyperadrenocorticism is diagnosed in about one in four 
hundred UK dogs and that the Bichon Frise, Standard Dachshund and the Yorkshire Terrier 
show evidence of increased odds compared with other breeds. Dogs diagnosed with 
hyperadrenocorticism are more likely to be older, weigh under 20kg but be above their average 
breed bodyweights. These results may assist clinicians to balance their index of suspicion for 
this disease as well highlighting interesting features of hyperadrenocorticism in the dog which 




ACTH; adrenocorticotropic hormone 
ACVIM; American College of Veterinary Internal Medicine 
ATHAC; adrenal tumour hyperadrenocorticism 
CI; confidence interval 
EPR; electronic patient record 
HDDST; high dose dexamethasone suppression test 
KC; Kennel Club 
LDDST; low dose dexamethasone suppression test 
OR; odds ratio 
PMS; practice management system 
PTHAC; pituitary tumour hyperadrenocorticism 
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